Holen Sie sich die Stockscreener-App
0.2347
0.43%
0.0003
Schlusskurs vom Vortag:
$0.235
Offen:
$0.248
24-Stunden-Volumen:
245.90K
Relative Volume:
0.11
Marktkapitalisierung:
$11.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.11M
KGV:
-0.054
EPS:
-4.347
Netto-Cashflow:
$-12.04M
1W Leistung:
-12.92%
1M Leistung:
-14.83%
6M Leistung:
-77.94%
1J Leistung:
-68.47%
1-Tages-Spanne:
$0.2321
$0.248
1-Wochen-Bereich:
$0.23
$0.2785
52-Wochen-Spanne:
$0.1772
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Firmenname
AEON Biopharma Inc.
Sektor
Branche
Telefon
(949) 354-6499
Adresse
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.2365 | 11.72M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
522.04 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
799.73 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.06 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.27 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | H.C. Wainwright | Buy |
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX - marketscreener.com
Laidlaw initiates Aeon Biopharma stock coverage with buy rating By Investing.com - Investing.com UK
AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference - The Manila Times
AEON Biopharma to Host Investor Meetings at Lake Street Capital Markets’ 10th Annual BIG10 Conference - Quiver Quantitative
Insider Purchase: 10% Owner at $AEON Buys 1,150,000 Shares - Moomoo
AEON Biopharma names Paul Lee as acting chief regulatory officer By Investing.com - Investing.com Nigeria
AEON Biopharma names Paul Lee as acting chief regulatory officer - Investing.com
Aeon Biopharma director Timothy Lynch buys $243,455 in stock - Investing.com India
Timothy Lynch (NASDAQ: AEON) owns 13% and holds blocked warrants - Stock Titan
AEON Reports New Data on Botox Biosimilar - Orange County Business Journal
Lake Street Maintains AEON Biopharma(AEON.US) With Buy Rating, Maintains Target Price $1 - Moomoo
AEON Flat on BOTOX Developments - Baystreet.ca
META_TITLE_QUOTE - Yahoo Finance
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® - The Manila Times
AEON Biopharma (AEON) Steadies at $0.28 as Key Support HoldsVolume Gap - vinanet.vn
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution - Investing.com
H.C. Wainwright cuts Aeon Biopharma stock price target on dilution By Investing.com - Investing.com UK
AEON Biopharma (AEON) Holds Above $0.27 Support as Shares Edge Up 1.66%Extension Target - vinanet.vn
AEON Q4 2025 Earnings: Wider-than-Expected Loss of -$0.42 per Share as Revenue Remains Absent - vinanet.vn
H.C. Wainwright Maintains AEON Biopharma(AEON.US) With Buy Rating, Cuts Target Price to $1.2 - Moomoo
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma Q2 EPS $(0.02) beats $(0.12) estimate - scanx.trade
AEON Biopharma Reports Q2 Results, Advances ABP-450 Program - TipRanks
AEON Biopharma Q2 net loss narrows on warrant gain; cash runway extended - TradingView
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AEON BIOPHARMA INC Q2 EBIT USD -5.919 MILLION - Moomoo
Aeon Biopharma Inc (AEON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards - The Manila Times
Aeon Biopharma Inc (AEON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AEON Biopharma Regains NYSE American Listing Compliance - TipRanks
AEON Biopharma Regains NYSE American Compliance After Completing Public Offering - Quiver Quantitative
AEON Biopharma (NYSE American: AEON) lifts .BC indicator after $13.6M equity raise - Stock Titan
AEON Q4 2025 Earnings: Wider Loss of -$0.42 Per Share Overshadowed by 14.81% Stock SurgeHealthcare Earnings Report - vinanet.vn
AEON Q4 2025 Earnings: Deep EPS Miss Overshadowed by 14.81% Share RallyPeak Earnings Alert - vinanet.vn
AEON Biopharma, Inc. Revenue Breakdown – AMEX:AEON - TradingView
Aeon Biopharma Inc (AEON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AEON|Aeon Biopharma Inc|Price:0.257|Chg%:+0.006 - TradingKey
Aeon Biopharma Inc (AEON) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aeon Biopharma Inc (AEON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aeon Biopharma Inc (AEON) Income Statement - TradingKey
Aeon Biopharma Inc (AEON) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards - GlobeNewswire Inc.
Aeon Biopharma Inc (AEON) Balance Sheet - TradingKey
Aeon Biopharma Inc (AEON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aeon Biopharma Inc (AEON) Cash Flow - TradingKey
AEON|Aeon Biopharma Inc|Price:0.241|Chg%:-0.014 - TradingKey
AEON Biopharma, Inc. Revenue Breakdown – BOATS:AEON - TradingView
Aeon Biopharma Inc (AEON) Institutional Confidence - TradingKey
Aeon Biopharma Inc (AEON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AEON|Aeon Biopharma Inc|Price:0.295|Chg%:+0.005 - TradingKey
AEON Biopharma boosts liquidity with additional share sale - The Globe and Mail
Finanzdaten der AEON Biopharma Inc.-Aktie (AEON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
1.02%
Kapitalisierung:
|
Volumen (24h):